Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 217-1222

  Ayaki, Masahiko ^a   Iwasawa, Atsuo ^b   Inoue, Yoichi ^c  

^a SAITAMA NATIONAL HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Olympia Eye Hospital   (Japan)

Author keywords

Cell viability score; Eye drop; Preservatives

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; DORZOLAMIDE; LATANOPROST; TIMOLOL MALEATE; TRAVOPROST;

ARTICLE; CELL CULTURE; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CULTURE MEDIUM; ENDOTHELIUM CELL; EYEBANK; HUMAN; HUMAN CELL; IN VITRO STUDY; TOXICITY TESTING;

EID: 78650694957     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S13708     Document Type: Article

References (35)

1. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles, and preservatives. Surv Ophthalmol. 1980;25:15-30.
2. Aoyama Y, Motoki M, Hashimoto M. Effect of various anti-glaucoma eyedrops on human corneal epithelial cells. Nippon Ganka Gakkai Zasshi. 2004;108:75-83.
3. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
4. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450.
5. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad, and the ugly. Prog Retin Eye Res. 2010;29:312-334.
6. Pfister RR, Burstein NL. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol. 1976;15:246-259.
7. Chou A, Hori S, Takase M. Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies. Jpn J Ophthalmol. 1985;29:13-23.
8. de Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94.
9. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486-490.
10. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360-1368.
11. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128.
12. Nuyts RM, Pels E, Greve EL. The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr Eye Res. 1992;11:565-570.
13. Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of eye drops with and without preservatives for human corneal endothelial cells, epithelial cells, and conjunctival epithelial cells. Exp Clin Ophthalmol. 2008;36:553-559.
14. Ayaki M, Noda Y, Yaguchi S, et al. Cytotoxicity of antiglaucoma eye drops for human corneal endothelial cells. Nippon Ganka Gakkai Zasshi. 2009;113:576-582.
15. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res. 1989;49:1-12.
16. Baratz KH, Nau CB, Winter EJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006;25:1046-1052.
17. Ayaki M, Shimada K, Yaguchi S, Koide R, Iwasawa A. Corneal and conjunctival toxicity of disinfectants-assessing safety for use with ophthalmic surgical instruments. Regul Toxicol Pharmacol. 2007;48:292-295.
18. Ayaki M, Soda M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free eye drops in four corneoconjunctival cell lines. Clin Ophthalmol. In press.
19. Ayaki M, Iwasawa A, Yaguchi S, Koide R. Preserved and unpreserved 12 anti-allergic eye drops and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci. In press.
20. Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analogue eye drops (tafluprost, latanoprost, travoprost, and unoproston) preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol. In press.
21. Liu H, Routley I, Teichmann KD.Toxic endothelial cell destruction from intraocular benzalkonium chloride. J Cataract Refract Surg. 2001;27:1746-1750.
22. Eleftheriadis H, Cheong M, Sandeman S, et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. Br J Ophthalmol. 2002;86(3):299-305.
23. Hughes EH, Pretorius M, Eleftheriadis H, Liu CS. Long-term recovery of the human corneal endothelium after toxic injury by benzalkonium chloride. Br J Ophthalmol. 2007;91(11):1460-1463.
24. Lemp MA, Zimmerman LE. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol. 1988;105:670-673.
25. Lavine JB, Binder PS, Wickham MG. Antimicrobials and the corneal endothelium. Ann Ophthalmol. 1979;11(10):1517-1528.
26. Vareilles P, Silverstone D, Plazonnet B, Le Douarec JC, Sears ML, Stone CA. Comparison of the effects of timolol and other adrenergic agents on intraocular pressure in the rabbit. Invest Ophthalmol Vis Sci. 1977;16:987-996.
27. Araie M, Takase M, Sakai Y, Ishii Y, Yokoyama Y, Kitagawa M. Betaadrenergic blockers: ocular penetration and binding to the uveal pigment. Jpn J Ophthalmol. 1982;26:248-263.
28. Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000;32:3-8.
29. Lass JH, Khosrof SA, Laurence JK, Horwitz B, Ghosh K, Adamsons I. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998;116:1003-1010.
30. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.
31. Giasson CJ, Nguyen TQ, Boisjoly HM, Lesk MR, Amyot M, Charest M. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:144-150.
32. Egan CA, Hodge DO, McLaren JW, Bourne WM. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest Ophthalmol Vis Sci. 1998;39:23-29.
33. Inoue K, Okugawa K, Oshika T, Amano S. Influence of dorzolamide on corneal endothelium. Jpn J Ophthalmol. 2003;47:129-133.
34. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343.
35. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:4594-4599.